The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Association of Serum Digoxin Concentration and Outcomes in Patients With Heart Failure
Abstract
Context: The Digitalis Investigation Group (DIG) trial reported that digoxin provided no overall mortality benefit and only a modest reduction in hospitalizations among patients with heart failure and depressed left ventricular systolic function. The clinical outcomes associated with digoxin therapy at different serum concentrations in the DIG trial have not been assessed. Objective: To assess variations in serum digoxin concentration (SDC) and their association with mortality and hospitalization in patients with heart failure. Design, Setting, and Patients: Post hoc analysis of the randomized, double-blinded, placebo-controlled DIG trial, conducted from August 1991 to December 1995, with the main analysis restricted to men with a left ventricular ejection fraction of 45% or less (n = 3782). Patients randomly assigned to receive digoxin were divided into 3 groups based on SDC at 1 month (0.5-0.8 ng/mL, n = 572; 0.9-1.1 ng/mL, n = 322; and ≥1.2 ng/mL, n = 277) and compared with patients randomly assigned to receive placebo (n = 2611). Main Outcome Measure: All-cause mortality at a mean follow-up of 37 months. Results: Higher SDCs were associated with increased crude all-cause mortality rates (0.5-0.8 ng/mL, 29.9%; 0.9-1.1 ng/mL, 38.8%; and ≥1.2 ng/mL, 48.0%; P = .006 for trend). Patients with SDCs of 0.5 to 0.8 ng/mL had a 6.3% (95% confidence interval [CI], 2.1%-10.5%) lower mortality rate compared with patients receiving placebo. Digoxin was not associated with a reduction in mortality among patients with SDCs of 0.9 to 1.1 ng/mL (2.6% increase; 95% CI, − 3.0% to 8.3%), whereas patients with SDCs of 1.2 ng/mL and higher had an 11.8% (95% CI, 5.7%-18.0%) higher absolute mortality rate than patients receiving placebo. The association between SDC and mortality persisted after multivariable adjustment (SDC 0.5-0.8 ng/mL hazard ratio [HR] 0.80, 95% CI, 0.68-0.94; SDC 0.9-1.1 ng/mL HR 0.89, 95% CI, 0.74-1.08; SDC ≥1.2 ng/mL HR 1.16, 95% CI, 0.96-1.39; and HR of 1.00 [referent] for placebo). Conclusions: Our findings demonstrate that higher SDCs were associated with increased mortality and suggest that the effectiveness of digoxin therapy in men with heart failure and a left ventricular ejection fraction of 45% or less may be optimized in the SDC range of 0.5 to 0.8 ng/mL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The effect of digoxin on mortality and morbidity in patients with heart failure
(1997) · New England Journal of Medicine · doi:10.1056/nejm199702203360801 · Cited by 3,016
Hunt, S. A., Baker, D. W., Chin, M. H., Cinquegrani, M. P., Feldman, A. M., Francis, G. S., Ganiats, T. G., Goldstein, S., Gregoratos, G., Jessup, M. L., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01683-7 · Cited by 1,912
Regression Using Fractional Polynomials of Continuous Covariates: Parsimonious Parametric Modelling
Royston, P., & Altman, D. G. (1994) · Applied Statistics · doi:10.2307/2986270 · Cited by 1,798
Committee Members, Hunt, S. A., Baker, D. W., Chin, M. H., Cinquegrani, M. P., Feldmanmd, A. M., Francis, G. S., Ganiats, T. G., Goldstein, S., Gregoratos, G., et al. (2001) · Circulation · doi:10.1161/hc4901.102568 · Cited by 1,442
Packer, M. (1992) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(92)90167-l · Cited by 1,056
Sex-Based Differences in the Effect of Digoxin for the Treatment of Heart Failure
Rathore, S. S., Wang, Y., & Krumholz, H. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021266 · Cited by 690
Self-citationA Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart Failure
Cohn, J. N., Goldstein, S. O., Greenberg, B. H., Lorell, B. H., Bourge, R. C., Jaski, B. E., Gottlieb, S. O., McGrew, F., DeMets, D. L., & White, B. G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812173392503 · Cited by 613
Hauptman, P. J., & Kelly, R. A. (1999) · Circulation · doi:10.1161/01.cir.99.9.1265 · Cited by 268
Fortnightly Review: Diagnosis and management of heart failure
Dargie, H. J., & McMurray, J. J. V. (1994) · BMJ · doi:10.1136/bmj.308.6924.321 · Cited by 197
Digoxin. A neurohormonal modulator in heart failure?
Gheorghiade, M., & Ferguson, D. (1991) · Circulation · doi:10.1161/01.cir.84.5.2181 · Cited by 197
van Veldhuisen, D. J., Man in't Veld, A. J., Dunselman, P. H. J. M., Lok, D. J. A., Dohmen, H. J. M., Poortermans, J. C., Withagen, A. J. A. M., Pasteuning, W. H., Brouwer, J., & Lie, K. I. (1993) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(93)90579-p · Cited by 163
Clinical benefits of low serum digoxin concentrations in heart failure
Adams, K. F., Gheorghiade, M., Uretsky, B. F., Patterson, J. H., Schwartz, T. A., & Young, J. B. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01708-4 · Cited by 160
A nomogram for digoxin therapy
Jelliffe, R. W., & Brooker, G. (1974) · The American Journal of Medicine · doi:10.1016/0002-9343(74)90769-4 · Cited by 149
Slatton, M. L., Irani, W. N., HALL, S. A., Marcoux, L., Page, R. L., Grayburn, P. A., & Eichhorn, E. J. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00057-0 · Cited by 133
The Digitalis Investigation Group (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00065-8 · Cited by 133
Gheorghiade, M., Hall, V. B., Jacobsen, G., Alam, M., Rosman, H., & Goldstein, S. (1995) · Circulation · doi:10.1161/01.cir.92.7.1801 · Cited by 121
Digoxin reduces cardiac sympathetic activity in severe congestive heart failure
Newton, G. E., Tong, J., Schofield, A. M., Baines, A. D., Floras, J. S., & Parker, J. D. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(96)00120-9 · Cited by 115
The development of positive inotropic agents for chronic heart failure: How have we gone astray?
Packer, M. (1993) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(93)90474-f · Cited by 112
Part 5. Evaluation of Laboratory Measurementsfor Clinical Assessment of Kidney Disease
(2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.30944 · Cited by 112
Digitalis Investigation Group (DIG) trial: A stimulus for further research
Gheorghiade, M., & Pitt, B. (1997) · American Heart Journal · doi:10.1016/s0002-8703(97)70100-5 · Cited by 75
Liu, P. J., Arnold, M., Belenkie, I., Howlett, J. G., Huckell, V. F., Ignazewski, A., LeBlanc, M. H., McKelvie, R. S., Niznick, J., Parker, J. D., et al. (2001) · PubMed · Cited by 71
Diagnosis and management of heart failure
Lakasing, E., & Francis, H. (2006) · Primary Health Care · doi:10.7748/phc2006.06.16.5.36.c611 · Cited by 55
Effect of Digoxin on Ejection Fraction in Elderly Patients with Congestive Heart Failure
Ware, J. A., Snow, E., Luchi, J. M., & Luchi, R. J. (1984) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1984.tb02249.x · Cited by 49
Therapeutic Range of Digoxin's Efficacy in Heart Failure: What Is the Evidence?
Terra, S. G., Washam, J. B., Dunham, G. D., & Gattis, W. A. (1999) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.15.1123.30570 · Cited by 35
Leor, J., Goldbourt, U., Rabinowitz, B., Reicher-Reiss, H., Boyko, V., Kaplinsky, E., Behar, S., & the SPRINT Study Group (1995) · Cardiovascular Drugs and Therapy · doi:10.1007/bf00878556 · Cited by 32
Low-dose digoxin in patients with heart failure
van Veldhuisen, D. J. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01710-2 · Cited by 25
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,115
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Hunt, S. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.022 · Cited by 4,154
Metadata
- Authors
- Rathore, S. S., Curtis, J. P., Wang, Y., Bristow, M. R., & Krumholz, H. M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2003-02-19
- Volume
- 289
- Issue
- 7
- Pages
- 871
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1970151280
- Cited by
- 772
- References
- 26
- FWCI
- 26.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.